Venus Medtech (Hangzhou) Inc. reported no changes to its share capital for the month ended 31 August 2026, maintaining a stable equity structure and affirming compliance with Hong Kong Stock Exchange listing rules.

Share Capital and Public Float • Authorised/registered capital stood at 441.01 million H-shares with a par value of RMB1, unchanged from the previous month. • The unlisted foreign-share tranche remained at 1,208 shares. • Issued H-shares totaled 441,010,235, with no treasury shares held. • Management confirmed the public float comfortably met the 25% minimum threshold required by the Exchange.

Equity Incentive Capacity • No share options were outstanding or exercised in August. • The 2023 Share Option Scheme still permits up to 44.10 million additional H-shares to be granted.

Repurchased but Un-cancelled Shares • A repurchase of 3.11 million H-shares executed in December 2021 remains pending cancellation; no further repurchase or cancellation activity occurred during the month.

Other Instruments • The company reported no outstanding warrants, convertible securities or other equity-linked instruments.

Regulatory Compliance Venus Medtech affirmed that all corporate actions disclosed have been duly authorised and remain fully compliant with Hong Kong listing regulations and applicable laws.

With no new share issuance, conversion, or treasury-share movements in August 2026, Venus Medtech’s capital base remained stable, underscoring management’s focus on maintaining shareholder structure and regulatory compliance.